Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Peristeri – page 85

1 033 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Peristeri at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Peristeri

Open in trial search

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Effects and Safety of Belimumab for Adults with Early Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Plasma cell myeloma

Not recruiting

Study on Iberdomide for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem Cell Transplantation

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Iberdomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:European Myeloma Network B.V.

Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Plasma cell myeloma

Not recruiting

Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:65+ years
  • Substances:Isatuximab
  • Sponsor:Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH

Endometrial cancer+2

Not recruiting

Study on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Selinexor
  • Sponsor:Karyopharm Therapeutics Inc.

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC

Study on the Effectiveness of Bortezomib, Rituximab, and Ibrutinib for Patients with Newly Diagnosed Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Peristeri

What the registry says about research in the country

01 Cardiovascular Diseases

In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.

  • Composite cardiovascular outcome assessment
  • Weekly dosing strategy
  • Integration with standard of care
  • Focus on heart‑failure subtypes

Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.

02 Nutritional and Metabolic Diseases

Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.

  • Weight‑loss non‑inferiority testing
  • Superiority versus placebo evaluation
  • Adjunct lifestyle intervention
  • Targeting overweight and obesity

The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.